Exact Sciences Corporation (EXAS) reported a net loss of 50 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. This quarter's loss was wider than the year-ago loss of 42 cents. Revenues in Detail First-quarter consolidated revenues were $637.5 million, up 5.8% on reported and core revenue basis year over year. The metric exceeded the Zacks Consensus Estimate by 2%. Segments in Detail Screening revenues, including laboratory service revenues from Cologuard, PreventionGenetics a ...